title: [The influence of anti-interferon-alpha 2a antibodies in initial daily four-week interferon-alpha 2a therapy for chronic hepatitis C].
abstract: Thirty-two patients with chronic active hepatitis C were initially treated with 9 million units of interferon (IFN)-alpha 2a daily for 4 weeks and then thrice weekly for 20 weeks. The incidence of development and influence on clinical effectiveness of anti-IFN alpha 2a neutralizing antibodies measured by bioassay were investigated. Thirteen (41%) of the 32 patients developed antibodies, 4 (12.5%) of whom exhibited a high titer of 128 NU or greater. There was a significant difference (p < 0.05) between responders and non-responders in the low viral load group (less than 10(5) copies/50 microliters) in the incidence of antibody development, with antibodies present in 2 of the 9 responders (22%) and 5 of the 7 non-responders (71%). There was also a significant difference between the antibody-negative and antibody-positive patients in circulating HCV-RNA, 2-5AS activity and average ALT levels at the latter half of treatment. In addition, 2-5AS activity was significantly lower (p < 0.05) at completion of treatment in the high antibody titer group (128 NU or greater) than in the low antibody titer group. These results indicate that the development of anti-IFN neutralizing antibodies had a definite influence on the clinical course of IFN treatment for chronic hepatitis C.
authors.affiliation: Department of Gastroenterology, Yodogawa Christian Hospital.
authors.forename: D
authors.initials: D
authors.lastname: Habu
authors.forename: M
authors.initials: M
authors.lastname: Mizuno
authors.forename: K
authors.initials: K
authors.lastname: Ohnishi
authors.forename: A
authors.initials: A
authors.lastname: Watanabe
authors.forename: J
authors.initials: J
authors.lastname: Son
authors.forename: M
authors.initials: M
authors.lastname: Iwano
authors.forename: R
authors.initials: R
authors.lastname: Murakoshi
authors.forename: T
authors.initials: T
authors.lastname: Takino
authors.forename: Y
authors.initials: Y
authors.lastname: Mizuma
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
mesh_terms: D000328:Adult; D000368:Aged; D000906:Antibodies / Q000032:analysis*; D004334:Drug Administration Schedule; D005260:Female; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000276:immunology* / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins
chemical_list: D000906:Antibodies; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins